Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06370728 · ClinicalTrials.gov registry record · Phase 1

A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06370728: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT06370728 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06370728, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.

Primary Outcome

PK: AUC (0-∞) of Orforglipron

Conditions Studied

Healthy

Interventions

  • DRUG Orforglipron
  • DRUG Carbamazepine

Study Locations (1)

Texas

  • ICON Early Phase Services - San Antonio

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-06
Est. Completion 2024-07-23
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT06370728 record still lists

NCT06370728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Orforglipron is the first listed.

NCT06370728 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06370728 about?

NCT06370728 is a clinical study titled "A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants". The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given...

What is the current status of trial NCT06370728?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-05-06. Estimated completion is 2024-07-23.

What conditions does trial NCT06370728 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06370728?

The interventions under investigation include: Orforglipron (DRUG), Carbamazepine (DRUG).

Who is sponsoring clinical trial NCT06370728?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06370728 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06370728's enrollment target sits among peer trials

30 678th of 1090 higher than 363 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06370728, the US trial registry maintained by the National Library of Medicine. NCT06370728 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.